Weekly Digests

2025

July

Meet the newest T cell checkpoint: CD38

July 23, 2025

Immune checkpoint blockade (ICB) can unleash immune responses against a variety of cancers, but its efficacy is often limited by T cell exhaustion. In addition to well established checkpoints like PD-1 and CTLA-4, T cell exhaustion has also been linked to CD38 and NAD+. In recent work published in Cell Reports Medicine, Revach...

Vaccine with ICB sidekick unlock anti-melanoma T cell immunity

July 16, 2025

While personalized neoantigen vaccines have great potential, T cell responses induced by these vaccines often lack strength. Blass, Keskin, et al. aimed to improve T cell antitumor immunity by optimizing vaccine adjuvants and combining the vaccine with ICB. The results of their phase 1 trial in patients with melanoma were recently published in...

Mutant p53 doesn’t just lose functions - it gains them

July 9, 2025

Mutations in the p53 gene are well known drivers of cancer due to the loss of tumor suppressor functions that are maintained by wild-type p53. However, in recent investigations, Mahat et al. found that a common mutant p53, p53R175H in humans and p53R172H in mice, also gained functions that supported the development of...

CD8s get by without a little help from their friends

July 2, 2025

During acute infections, the primary immune response depends on CD4+ T cells providing help to CD8+ T cells. However, many effector CD8+ T cells (Teff) can respond to pathogens independently of helper responses, but these cells respond poorly to pathogen rechallenge. Van der Heide et al. investigated this helpless CD8+ T memory (Tmem)...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.